









Markets
/
Stocks
/
nasdaq-bysi
/

Beyondspring Inc

BYSI

1.920USD

+0.200+11.63%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

77.42MMarket Cap

LossP/E TTM



Beyondspring Inc

1.920

+0.200+11.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

248 / 506

Overall Ranking

404 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Undervalued

The company’s latest PE is -68.04, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.19M shares, decreasing 3.13% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 523.70K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.58.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.85, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.85

Change



Financials

9.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -60.95, which is -97.48% below the recent high of -1.53 and 89.11% above the recent low of -6.64.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 248/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.88, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.94 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.88

Change

0.83

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.018

Neutral

RSI(14)

52.646

Neutral

STOCH(KDJ)(9,3,3)

44.139

Buy

ATR(14)

0.124

Low Volatility

CCI(14)

-5.726

Neutral

Williams %R

24.242

Buy

TRIX(12,20)

-0.170

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.840

Buy

MA10

1.864

Buy

MA20

1.834

Buy

MA50

1.944

Sell

MA100

2.020

Sell

MA200

1.818

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Decheng Capital LLC

4.88M

-1.52%

Huang (Lan)

4.26M

Jia (Linqing)

1.78M

+0.00%

BlackRock Institutional Trust Company, N.A.

115.97K

-0.93%

Geode Capital Management, L.L.C.

24.37K

BlackRock Financial Management, Inc.

90.54K

Fabbio (Patrick)

53.86K

+119.03%

Majeti (Jiangwen)

50.91K

Tanaka Capital Management, Inc.

26.30K

-10.78%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.18, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.